ADMA Biologics (ADMA)
(Delayed Data from NSDQ)
$17.22 USD
-0.02 (-0.12%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $17.22 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$17.22 USD
-0.02 (-0.12%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $17.22 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth A Momentum B VGM
Zacks News
Adma Biologics (ADMA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Adma Biologics (ADMA) closed at $3.78 in the latest trading session, marking a -0.26% move from the prior day.
Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Atreca (BCEL) Suspends Lead Drug Evaluation, Stock Falls 37%
by Zacks Equity Research
Atreca (BCEL) suspends the development of only pipeline candidate, ATRC-101, in clinical evaluation, as part of its business restructuring efforts and cuts headcount by 40%. The stock falls 37%.
Catalyst (CPRX) Q2 Earnings & Sales Top, 2023 Outlook Raised
by Zacks Equity Research
Catalyst (CPRX) reports better-than-expected second-quarter 2023 results. Management raises full-year 2023 guidance.
Novo Nordisk (NVO) Q2 Earnings and Sales Miss, 2023 View Up
by Zacks Equity Research
Novo Nordisk (NVO) reports weaker-than-expected second-quarter 2023 results, missing both earnings and sales estimates. Management, however, raises 2023 guidance.
Is ADMA Biologics (ADMA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Adma Biologics (ADMA) and Align Technology (ALGN) have performed compared to their sector so far this year.
Adma Biologics (ADMA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Adma Biologics (ADMA) delivered earnings and revenue surprises of 0% and 8.43%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Zoetis' (ZTS) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zoetis (ZTS) reports better-than-expected second-quarter 2023 results, beating both earnings and revenue estimates, primarily driven by the sales of its key dermatology products.
Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of 25.15% and 67.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Intra-Cellular (ITCI) Q2 Earnings & Sales Top, '23 View Raised
by Zacks Equity Research
Intra-Cellular (ITCI) reports better-than-expected second-quarter results. Caplyta sales continue to drive growth. The company raises its financial outlook for full-year Caplyta sales.
Acadia (ACAD) Q2 Earnings & Revenues Beat Estimates, '23 View Up
by Zacks Equity Research
Acadia (ACAD) reports better-than-expected second-quarter 2023 results, raising its financial guidance for the year. The company also provides updates on its pipeline.
Pacira (PCRX) Q2 Earnings and Sales Miss, '23 View Updated
by Zacks Equity Research
Pacira (PCRX) announces weaker-than-expected second-quarter 2023 results. The company updates its 2023 financial guidance.
Apellis (APLS) Q2 Earnings Top, Syfovre Sales Boost Revenues
by Zacks Equity Research
Apellis (APLS) reports better-than-expected second-quarter 2023 results. However, the stock falls 20% due to ambiguity surrounding Syfovre's safety profile.
ADMA Biologics (ADMA) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
On ADMA Biologics' (ADMA) Q2 earnings call, investors will likely focus on the sales performance of its immune deficiency disorder drugs.
Adma Biologics (ADMA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Adma Biologics (ADMA) closed the most recent trading day at $3.76, moving +0.53% from the previous trading session.
Adma Biologics (ADMA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Adma Biologics (ADMA) closed at $3.49, marking a +0.58% move from the previous day.
New Strong Buy Stocks for July 7th
by Zacks Equity Research
ADMA, APOG, KIND, JBL and OII have been added to the Zacks Rank #1 (Strong Buy) List on July 7, 2023.
Vertex (VRTX) Gets Nod in EU for Orkambi Expanded Indication
by Zacks Equity Research
Vertex's (VRTX) Orkambi gets approval from the European Commission in the EU for the treatment of cystic fibrosis in patients (aged 1 to <2 years) who have two copies of the F508del mutation.
CRISPR (CRSP) Shares Rise 24% in the Last Quarter: Here's Why
by Zacks Equity Research
Shares of CRISPR (CRSP) surge 24% in the last quarter after the company, along with Vertex, provides positive regulatory updates on exa-cel BLAs in SCD and TDT treatment.
Alnylam (ALNY) Announces FDA Committee Onpattro sNDA Review Date
by Zacks Equity Research
Alnylam (ALNY) reports that the FDA has set Sep 13, 2023, as the day for the meeting of the Advisory Committee to review its sNDA application for patisiran in treating the cardiomyopathy of ATTR amyloidosis.
Kintara (KTRA) Rises 41% on $2M Grant for Breast Cancer Therapy
by Zacks Equity Research
Kintara (KTRA) receives a $2 million grant from the National Institutes of Health to develop its breast cancer treatment candidate, REM-001. The stock surges 41%.
Liquidia (LQDA) Up on Deal With Pharmosa to Co-Develop PH Drug
by Zacks Equity Research
Liquidia (LQDA) signs an exclusive licensing agreement with Pharmosa to jointly develop and commercialize PAH and PH-ILD treatment candidate, L606, in North America. Shares of the company rise 11%.
Aeglea (AGLE) Soars 329% on Acquiring Spyre Therapeutics
by Zacks Equity Research
Aeglea's (AGLE) shares surge as it acquires Spyre Therapeutics, a private company that focuses on developing antibody therapeutics for inflammatory bowel disease.
uniQure (QURE) Falls on Mixed Huntington's Disease Study Results
by Zacks Equity Research
uniQure (QURE) stock declines after the company announces mixed results from its biomarkers analysis in the early-to-mid-stage study of AMT-130 in Huntington's disease.
Amgen's (AMGN) Blincyto sBLA Gets FDA Nod in Treating Leukemia
by Zacks Equity Research
Amgen (AMGN) announces full approval of its sBLA for Blincyto as an immune-oncology therapy for treating adults and pediatric patients with CD19-positive B-cell precursor acute lymphoblastic leukemia.